Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Juan, Domingo Alonso"'
Autor:
null Pedro Salinas Hernández, null Rafael Trujillo Vilchez, null Antonio Arriví García-Ramos, null Rosana Grande Ladron de Guevara, null Angeles Rodríguez Jaraiz, null Pedro Gallurt Moreira, null Jose Maria Vieitez de Prado, null Miguel Ruiz López de Tejada, null Antonio Irigoyen Medina, null Juan Manuel Campos Cervera, null Juan Carlos Cámara Vicario, null Uriel Bohn Sarmiento, null Pedro López Tendero, null Juan Domingo Alonso Lajara, null Ana León Carbonero, null Marisa García de Paredes, null Juan de Alvaro Liaño, null Asunción Juarez Marroquí, null Luis López Gómez, null Diego Soto de Prado Otero
Publikováno v:
Journal of Analytical Oncology. 2
Background: This observational study evaluated the efficacy and safety of treatment with bevacizumab plus chemotherapy until disease progression (PD) in Spanish patients with metastatic colorectal cancer (mCRC). Methods: This multicentre, retrospecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc0259bd03b0cd2aceb30a9cbfb1c564
https://doi.org/10.6000/1927-7229.2013.02.03.1
https://doi.org/10.6000/1927-7229.2013.02.03.1
Autor:
José Ignacio, Mayordomo, Andrés, López, Núria, Viñolas, Javier, Castellanos, Sonia, Pernas, Juan, Domingo Alonso, Adolfo, Frau, Miquel, Layola, José, Antonio Gasquet, Jordi, Sánchez, M J, Lamas
Publikováno v:
Current medical research and opinion. 25(10)
Febrile neutropenia (FN) is associated with disruption of planned chemotherapy and increased management costs. However, the economic impact of FN in Spanish clinical practice has not been documented hitherto.A multicenter, retrospective chart review
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b52fc3aa311744c15d9928e7137c55ed
https://pubmed.ncbi.nlm.nih.gov/19722781
https://pubmed.ncbi.nlm.nih.gov/19722781
Publikováno v:
Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 8(10)
Paraneoplastic neurological syndromes constitute an unusual manifestation of cancer. The objective of this case report is to debate the association between rituximab therapy and Guillain-Barre syndrome. We present the case of a 57 years old patient,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::def228e60b08acd7855b7fd868ab7e21
https://pubmed.ncbi.nlm.nih.gov/17074678
https://pubmed.ncbi.nlm.nih.gov/17074678
Autor:
Juan José Reina, Isabel Sevilla, Juan Domingo Alonso-Guadalajara, Pilar Alfonso, Jaume Capdevila, Paula Jimenez, Luis M. Antón Aparicio, Vicente Alonso, Enrique Grande, Jose Luis Manzano
Publikováno v:
Journal of Clinical Oncology. 30:e14671-e14671
e14671 Background: Analysis of the mechanisms of action of somatostatin analogs (SSAs) and mTOR inhibitors or tyrosine kinase inhibitors suggest that they may provide synergistic effects when used in combination for the treatment of pts with NETs. Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e32d7c1a923e9f2c0c080e3777ff85ed
https://doi.org/10.1200/jco.2012.30.15_suppl.e14671
https://doi.org/10.1200/jco.2012.30.15_suppl.e14671